Constellation Pharmaceuticals (CNST) Weakness is a Buying Opportunity - RBC
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $53.00 price target on Constellation Pharmaceuticals (NASDAQ: CNST), saying weakness ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
